Overview

Pharmacokinetic Characterization of Intramuscular Olanzapine Depot

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goals of this study are to: Determine the blood levels of intramuscular (IM) olanzapine depot in patients at different points in time after an injection, and compare these levels to the amount of olanzapine in the blood of patients after treated by oral administration with Zyprexa (olanzapine) tablets or by intramuscular administration with Zyprexa IntraMuscular (olanzapine for injection).
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine